<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>將其添加為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>薩托里烏斯表示，基於對未來市場發展的評估，公司預計其可服務市場在中期內將以每年約 7% 至 9% 的速度增長。在此背景下，薩托里烏斯為 2027 年及以後的時期設定了新的中期目標。管理層預計，公司將持續超越其可服務市場，每年增長約 100 至 200 個基點，從而實現集團層面以固定貨幣計算的有機銷售收入增長率為每年 8% 至 11%。此外，集團層面的基礎 EBITDA 利潤率預計每年將增長約 50 至 75 個基點。</p>
<p>公司旨在通過加強在過程強化、一次性技術和細胞分析等關鍵應用中的領導地位來鞏固其核心業務。薩托里烏斯計劃進一步發展一些新興業務，包括先進療法解決方案、先進細胞模型、過程分析技術以及分析表徵和質量控制平台。</p>
<p>在最後一次收盤時，薩托里烏斯的股票交易價格為 209.00 歐元，下跌 0.33%。</p>
<p>欲獲取更多健康新聞，請訪問 rttnews.com。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

<p>薩托里烏斯（Sartorius）設定了新的中期財務目標，預計其可服務市場將以每年 7-9% 的速度增長。該公司旨在超越這一增長，目標是每年實現 100-200 個基點的增長，預計從 2027 年起，公司的有機銷售收入年增長率將達到 8-11%。此外，薩托里烏斯預計其基礎 EBITDA 利潤率將每年增加 50-75 個基點。公司將重點加強核心業務領域，並開發先進療法解決方案和分析技術等新興領域。薩托里烏斯的股票最近交易價格為 209.00 歐元，下跌 0.33%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>將其添加為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Sartorius said, based on its assessment of future market development, the company expects its addressable markets to grow at a rate of approximately 7 to 9 percent per year over the medium term. Against this backdrop, Sartorius introduced a new medium-term ambition for the period from 2027 onwards. Management expects the company to consistently outgrow its addressable markets by around 100 to 200 basis points per year leading to an organic sales revenue growth in constant currencies of 8 to 11 percent per year at group level. Also, underlying EBITDA margin at group level is supposed to grow by approximately 50 to 75 basis points per year.</p>
<div class="lb-trans"><p>薩托里烏斯表示，基於對未來市場發展的評估，公司預計其可服務市場在中期內將以每年約 7% 至 9% 的速度增長。在此背景下，薩托里烏斯為 2027 年及以後的時期設定了新的中期目標。管理層預計，公司將持續超越其可服務市場，每年增長約 100 至 200 個基點，從而實現集團層面以固定貨幣計算的有機銷售收入增長率為每年 8% 至 11%。此外，集團層面的基礎 EBITDA 利潤率預計每年將增長約 50 至 75 個基點。</p>
</div><p>The company aims to strengthen its core business by reinforcing its leadership positions in mission-critical applications in process intensification, single-use technologies and cell analytics. Sartorius plans to further develop select emerging businesses, including advanced therapy solutions, advanced cell models, process analytical technologies and analytical characterization and quality control platforms.</p>
<div class="lb-trans"><p>公司旨在通過加強在過程強化、一次性技術和細胞分析等關鍵應用中的領導地位來鞏固其核心業務。薩托里烏斯計劃進一步發展一些新興業務，包括先進療法解決方案、先進細胞模型、過程分析技術以及分析表徵和質量控制平台。</p>
</div><p>At last close, Sartorius shares were trading at 209.00 euros, down 0.33%.</p>
<div class="lb-trans"><p>在最後一次收盤時，薩托里烏斯的股票交易價格為 209.00 歐元，下跌 0.33%。</p>
</div><p>For More Such Health News, visit rttnews.com.</p>
<div class="lb-trans"><p>欲獲取更多健康新聞，請訪問 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

Sartorius 發佈了新的中期財務目標